Marker Therapeutics to Host Business Update Conference Call and Webcast on Thursday, March 28th
MEDIA COVERAGE
Companies Merge to Implement Baylor College of Medicine-Developed Therapies for Cancer
The researchers developed a novel therapy for cancer patients that harnesses the patient’s own immune system to fight cancer in a natural way. This therapy uses a ‘natural’ T cell response that does not require genetic engineering.
New Details Emerge on TapImmune Merger
TapImmune Inc., Jacksonville’s publicly traded developer of cancer-fighting immunotherapies, announced in May that it was merging with Minnesota-based Marker Therapeutics Inc., another developer of immunotherapies.
No Revenue, but TapImmune Leads Pack
Company developing immunotherapy treatments for cancer up 139 percent this year.
This Jacksonville Company’s Stock is Surging as the Market sees there’s “No Competitor”
TapImmune Inc. stock has blossomed in the month since it announced it will merge with a company producing similar cancer-fighting treatments, begin a strategic alliance with Baylor College of Medicine and move to Houston. The stock has more than tripled since the announcement and rose more than 18 percent Friday.
TapImmune Poised To Become A Cell Therapy Leader, WBB Securities Says In Upgrade
TapImmune will pursue a new approach to treating cancer through a proposed merger with privately held Marker Therapeutics, a WBB Securities analyst said in an upgrade note.
QUOTES
“I believe that the new therapies we are acquiring with Marker in this transaction represent the next major leap forward in cell therapy for cancer. The merger adds to our product pipeline a synergistic portfolio of highly-differentiated T cell therapies that has demonstrated potentially groundbreaking results in early clinical trials in lymphoma, acute myeloid leukemia (AML), and multiple myeloma.”
Peter L. Hoang, President & CEO
“With this merger, I believe we have the opportunity to significantly disrupt the CAR-T and TCR field. Compared to current gene-modified T cell therapies such as CAR-T and TCR, the therapies we are acquiring in this transaction are highly efficacious and extremely durable, without the need for lymphodepletion before infusion, non gene-modified, significantly less toxic than CAR-T, multi-antigen specific, capable of driving an endogenous immune response, and capable of addressing patients currently inaccessible to CAR-T therapies.”
Peter L. Hoang, President & CEO
LOGO USAGE
COLORS
Primary Color
#233E7B
Secondary Color
#3D759B
Dark Color
#161819
TEAM PHOTOS
